IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Baldwin Investment Management LLC

Baldwin Investment Management LLC boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 8.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,548 shares of the medical research company’s stock after acquiring an additional 280 shares during the quarter. Baldwin Investment Management LLC’s holdings in IQVIA were worth $841,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. PGGM Investments grew its position in IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after buying an additional 4,326 shares in the last quarter. Simplify Asset Management Inc. lifted its position in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the period. Raymond James & Associates boosted its stake in IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after purchasing an additional 5,417 shares in the last quarter. Versor Investments LP acquired a new position in shares of IQVIA during the 3rd quarter valued at $1,328,000. Finally, Gradient Investments LLC raised its stake in shares of IQVIA by 15.6% in the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after buying an additional 6,134 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

NYSE IQV opened at $201.24 on Wednesday. The stock’s 50-day moving average is $221.18 and its two-hundred day moving average is $226.75. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The firm has a market cap of $36.53 billion, a P/E ratio of 26.41, a price-to-earnings-growth ratio of 2.10 and a beta of 1.51.

Analyst Upgrades and Downgrades

IQV has been the subject of several research reports. Redburn Atlantic initiated coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 target price for the company. Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Leerink Partners reissued an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Evercore ISI decreased their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Barclays cut their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.